Most research hands you a target price and asks you to trust it. Every report here ships with the working valuation model, open and adjustable. Disagree with an assumption, change it, and see what your own view is worth per share.
New coverage weekly. Every rating reviewed each quarter on results, and immediately on a material event.
We start where the sell side stops — US listings with thin or no analyst coverage, where an extra pair of eyes is actually worth something.
Author positions are published on every report, with a fixed no-trade window either side of publication.
Every rating, its date, its price and what happened next — kept public whether or not it flatters us.
Targets get published without the arithmetic behind them, so a reader has no way to tell a considered view from a guess. Coverage clusters on the same two hundred large caps, leaving the half of the US market with no analyst attention genuinely unexamined. And the author's own position — the single most useful piece of context a reader could have — is almost never disclosed.
This publication fixes all three, and treats the fixes as the product rather than the paperwork.